Intranasale Schmerzmittel in der Notfallmedizin – Was ist die Evidenz? Teil 2 Esketamin

Dieser Artikel ist die Fortsetzung des im Notarzt 01/2024 erschienenen Artikels über die Evidenz bei intranasalen Schmerzmitteln in der Notfallmedizin. Teil 1 [1] hat sich mit intranasalem Fentanyl beschäftigt. Im vorliegenden Artikel soll die aktuell verfügbare Evidenz für die intranasale Esketamin-Gabe näher betrachtet werden.

Publication History

Article published online:
03 June 2024

• Literatur

• 1 Ahne G, Dormann H, Neubert A. Intranasale Schmerzmittel in der Notfallmedizin – was ist die Evidenz? Teil 1 Fentanyl. NOTARZT 2024; 40: 13-16 DOI: 10.1055/a-2230-5541.
• 2 Pees C, Haas NA, Ewert P. et al. Comparison of analgesic/sedative effect of racemic ketamine and S(+)-ketamine during cardiac catheterization in newborns and children. Pediatr Cardiol 2003; 24: 424-429 DOI: 10.1007/s00246-002-0356-4. (PMID: 14627307)
• 3 Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI). S2k-Leitlinie Katastrophenmedizinische prähospitale Behandlungsleitlinien. Version 1.1. AWMF-Registernr. 001–043. 30.04.2023 Accessed April 05, 2024 at: https://register.awmf.org/de/leitlinien/detail/001-043
• 4 Choudhury D, Autry AE, Tolias KF. et al. Ketamine: Neuroprotective or Neurotoxic?. Front Neurosci 2021; 15: 672526 DOI: 10.3389/fnins.2021.672526. (PMID: 34566558)
• 5 Janssen-Cilag International NV. Spravato® 28 mg Nasenspray, Lösung. Fachinformation. 2023 Accessed April 05, 2024 at: https://static.janssen-emea.com/sites/default/files/Germany/SMPC/DE-PL-0062.pdf
• 6 Rote Liste® Service GmbH. Aktuelle Fachinformationen zu Fertigarzneimitteln. mit DocCheck-Passwort Accessed December 11, 2023 at: www.fachinfo.de
• 7 Ärztlicher Leiter Rettungsdienst (ÄLRD) Bayern. Medizinische Empfehlung der ÄLRD Bayern: Medikamente zur Anwendung nach §2a NotSanG. 30.03.2023 Accessed April 05, 2024 at: https://www.aelrd-bayern.de/images/2023-03-30_Medikamente_nach__2a_NotSanG_1.2_-_FINAL.pdf
• 8 Deutsche Gesellschaft für Kinder und Jugendmedizin e. V. (DGKJ). S2k-Leitlinie Medikamentensicherheit bei Kindernotfällen. Version 2.0. AWMF-Registernr. 001–033. 24.11.2021 Accessed April 05, 2024 at: https://register.awmf.org/de/leitlinien/detail/027-071
• 9 Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V. (DGPPN). S3-Leitlinie Verhinderung von Zwang: Prävention und Therapie aggressiven Verhaltens bei Erwachsenen. Version 2.0. 12.02.2018 Accessed April 05, 2024 at: https://register.awmf.org/de/leitlinien/detail/038-022
• 10 Sergentanis I, Vibert V, Costanza A. et al. [About the use of ketamine in emergency psychiatric settings]. Rev Med Suisse 2021; 17: 303-306 (PMID: 33586375)
• 11 Gliwitzky B, Olivieri M, Bathe J. et al. Intranasale Analgesie bei Säuglingen und Kleinkindern. Notfall Rettungsmed 2022; 25: 53-57
• 12 Kinderformularium.DE. Esketamin. Accessed April 05, 2024 at: https://kinderformularium.de/monographie/5321/esketamin
• 13 Johansson J, Sjöberg J, Nordgren M. et al. Prehospital analgesia using nasal administration of S-ketamine--a case series. Scand J Trauma Resusc Emerg Med 2013; 21: 38 DOI: 10.1186/1757-7241-21-38. (PMID: 23672762)
• 14 Whitley GA, Pilbery R. Pre-hospital intranasal analgesia for children suffering pain: a rapid evidence review. Br Paramed J 2019; 4: 24-34 DOI: 10.29045/14784726.2019.12.4.3.24. (PMID: 33447148)
• 15 Nikula A, Lundeberg S, Ryd Rinder M. et al. A randomized double-blind trial of intranasal dexmedetomidine versus intranasal esketamine for procedural sedation and analgesia in young children. Scand J Trauma Resusc Emerg Med 2024; 32: 16 DOI: 10.1186/s13049-024-01190-5. (PMID: 38439043)
• 16 Nemeth M, Jacobsen N, Bantel C. et al. Intranasal Analgesia and Sedation in Pediatric Emergency Care-A Prospective Observational Study on the Implementation of an Institutional Protocol in a Tertiary Children’s Hospital. Pediatr Emerg Care 2019; 35: 89-95 DOI: 10.1097/PEC.0000000000001017. (PMID: 28121974)
• 17 Wang J, Zeng J, Zhao N. et al. Intranasal esketamine combined with oral midazolam provides adequate sedation for outpatient pediatric dental procedures: a prospective cohort study. Int J Surg 2023; 109: 1893-1899 DOI: 10.1097/JS9.0000000000000340. (PMID: 37288546)
• 18 Lu X, Tang L, Lan H. et al. A Comparison of Intranasal Dexmedetomidine, Esketamine or a Dexmedetomidine-Esketamine Combination for Induction of Anaesthesia in Children: A Randomized Controlled Double-Blind Trial. Front Pharmacol 2021; 12: 808930 DOI: 10.3389/fphar.2021.808930. (PMID: 35185548)
• 19 Xin N, Xu H, Yue C. Comparison between dexmedetomidine and esketamine in pediatric dentistry surgery. Transl Pediatr 2021; 10: 3159-3165 DOI: 10.21037/tp-21-435. (PMID: 35070829)
• 20 Bian Y, Zhou S, Hou H. et al. The optimal dose of oral midazolam with or without intranasal S-ketamine for premedication in children: a randomised, double blinded, sequential dose-finding trial. Transl Pediatr 2021; 10: 2941-2951 DOI: 10.21037/tp-21-247. (PMID: 34976760)
• 21 Huang J, Liu D, Bai J. et al. Median effective dose of esketamine for intranasal premedication in children with congenital heart disease. BMC Anesthesiol 2023; 23: 129 DOI: 10.1186/s12871-023-02077-1. (PMID: 37076798)
• 22 Liu W, Sun R, Gao X. et al. Effects of preoperative nasal spray esketamine on separation anxiety and emergence agitation in pediatric strabismus surgery: A randomized clinical trial. Medicine (Baltimore) 2022; 101: e32280 DOI: 10.1097/MD.0000000000032280. (PMID: 36595799)
• 23 Boudieu L, Mennetrier M, Llorca PM. et al. The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review. Pharmaceutics 2023; 15: 2773 DOI: 10.3390/pharmaceutics15122773. (PMID: 38140113)
• 24 Zanza C, Saglietti F, Giamello JD. et al. Effectiveness of Intranasal Analgesia in the Emergency Department. Medicina (Kaunas) 2023; 59: 1746 DOI: 10.3390/medicina59101746. (PMID: 37893464)
• 25 Seak YS, Nor J, Tuan Kamauzaman TH. et al. Efficacy and Safety of Intranasal Ketamine for Acute Pain Management in the Emergency Setting: A Systematic Review and Meta-Analysis. J Clin Med 2021; 10: 3978D DOI: 10.3390/jcm10173978. (PMID: 34501425)
• 26 Prescott MG, Iakovleva E, Simpson MR. et al. Intranasal analgesia for acute moderate to severe pain in children – a systematic review and meta-analysis. BMC Pediatr 2023; 23: 405 DOI: 10.1186/s12887-023-04203-x. (PMID: 37596559)
• 27 Rached-d’Astous S, Finkelstein Y, Bailey B. et al. Intranasal ketamine for procedural sedation in children: An open-label multicenter clinical trial. Am J Emerg Med 2023; 67: 10-16 DOI: 10.1016/j.ajem.2023.01.046. (PMID: 36774905)
• 28 Poonai N, Canton K, Ali S. et al. Intranasal ketamine for procedural sedation and analgesia in children: A systematic review. PLoS One 2017; 12: e0173253 DOI: 10.1371/journal.pone.0173253. (PMID: 28319161)
• 29 Alanazi E. The Effectiveness of Ketamine Compared to Opioid Analgesics for management of acute pain in Children in The Emergency Department: systematic Review. Am J Emerg Med 2022; 61: 143-151 DOI: 10.1016/j.ajem.2022.08.004. (PMID: 36113377)
• 30 Dwivedi P, Patel TK, Bajpai V. et al. Efficacy and safety of intranasal ketamine compared with intranasal dexmedetomidine as a premedication before general anesthesia in pediatric patients: a systematic review and meta-analysis of randomized controlled trials. Can J Anaesth 2022; 69: 1405-1418 DOI: 10.1007/s12630-022-02305-1. (PMID: 35970989)
• 31 Weber F, Wulf H, el Saeidi G. Premedication with nasal s-ketamine and midazolam provides good conditions for induction of anesthesia in preschool children. Can J Anaesth 2003; 50: 470-475 DOI: 10.1007/BF03021058. (PMID: 12734155)
• 32 Tongbua S, Sri-On J, Thong-On K. et al. Non-inferiority of intranasal ketamine compared to intravenous morphine for musculoskeletal pain relief among older adults in an emergency department: a randomised controlled trial. Age Ageing 2022; 51: afac073 DOI: 10.1093/ageing/afac073. (PMID: 35348606)
• 33 Nasr Isfahani M, Shokoohi O, Golshani K. Intranasal ketamine versus intranasal fentanyl on pain management in isolated traumatic patients. J Res Med Sci 2022; 27: 1 DOI: 10.4103/jrms.JRMS_505_20. (PMID: 35342440)
• 34 Yuan H, Natekar A, Park J. et al. Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis. Reg Anesth Pain Med 2023; 48: 581-587 DOI: 10.1136/rapm-2022-104223. (PMID: 37253638)
• 35 Benish T, Villalobos D, Love S. et al. The THINK (Treatment of Headache with Intranasal Ketamine) Trial: A Randomized Controlled Trial Comparing Intranasal Ketamine with Intravenous Metoclopramide. J Emerg Med 2019; 56: 248-257.e1
• 36 Heydari F, Azizkhani R, Majidinejad S. et al. A comparative study of intranasal desmopressin and intranasal ketamine for pain management in renal colic patients: A randomized double-blind clinical trial. Clin Exp Emerg 2024; 11: 51-58
• 37 Sarvari HR, Baigrezaii H, Nazarianpirdosti M. et al. Comparison of the efficacy of intranasal ketamine versus intravenous ketorolac on acute non-traumatic headaches: a randomized double-blind clinical trial. Head Face Med 2022; 18: 1 DOI: 10.1186/s13005-021-00303-0. (PMID: 34980184)
• 38 Li X, Hua GC, Peng F. Efficacy of intranasal ketamine for acute pain management in adults: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2021; 25: 3286-3295 DOI: 10.26355/eurrev_202104_25738. (PMID: 33928616)
• 39 Ittner KP, Koppenberg J, Walter U. Indikationsfremde Anwendung von Medikamenten und Medizinprodukten in der Notfallmedizin. NOTARZT 2017; 33: 178-188 DOI: 10.1055/s-0043-115073.